W. Haeck

Synthesis of benzothiophene-based hydroxamic acids as potent and selective HDAC6 inhibitors.

K. De Bosscher, L. Van Den Bosch, T. Verhaeghe, 2015, Chemical communications.

Assessment of americium and curium transmutation in magnesia based targets in different spectral zones of an experimental accelerator driven system

H. Abderrahim, V. Sobolev, E. Malambu, 2006 .

Inhibition of histone deacetylase 6 (HDAC6) protects against vincristine-induced peripheral neuropathies and inhibits tumor growth

W. Robberecht, C. Mathieu, G. Cavaletti, 2018, Neurobiology of Disease.

Molecular Dissection of FUS Points at Synergistic Effect of Low-Complexity Domains in Toxicity

W. Robberecht, P. van Damme, P. Callaerts, 2018, Cell reports.

HDAC6 is a therapeutic target in mutant GARS-induced Charcot-Marie-Tooth disease

M. Z. Cader, W. Robberecht, P. van Damme, 2018, Brain : a journal of neurology.

Bicyclic-Capped Histone Deacetylase 6 Inhibitors with Improved Activity in a Model of Axonal Charcot-Marie-Tooth Disease.

G. Vistoli, A. Kozikowski, L. Van Den Bosch, 2016, ACS chemical neuroscience.

Oligodendrocyte dysfunction in the pathogenesis of amyotrophic lateral sclerosis.

W. Richardson, W. Robberecht, P. van Damme, 2013, Brain : a journal of neurology.

Synthesis and SAR assessment of novel Tubathian analogs in the pursuit of potent and selective HDAC6 inhibitors.

L. Van Den Bosch, T. Verhaeghe, T. Desmet, 2016, Organic & biomolecular chemistry.